# BATCH Q: Quality

## Finalised Guidelines (Step 4)

<table>
<thead>
<tr>
<th>Guideline Code</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1A(R2)</td>
<td>Stability Testing of New Drug Substances and Products (Second Revision)</td>
<td>Feb. 2003</td>
</tr>
<tr>
<td>Q1C</td>
<td>Stability Testing for New Dosage Forms</td>
<td>Nov. 1996</td>
</tr>
<tr>
<td>Q1E</td>
<td>Evaluation for Stability Data</td>
<td>Feb. 2003</td>
</tr>
<tr>
<td>Q1E*</td>
<td>Stability Data Package for Registration Applications in Climatic Zones III and IV</td>
<td>Feb. 2003</td>
</tr>
<tr>
<td></td>
<td><em>(Guideline withdrawn in June 2006).</em></td>
<td></td>
</tr>
<tr>
<td>Q2(R1)</td>
<td>Validation of Analytical Procedures: Text and Methodology</td>
<td>Oct. 1994</td>
</tr>
<tr>
<td></td>
<td><em>(The Addendum dated November 1996 has been incorporated into the core guideline in November 2005).</em></td>
<td></td>
</tr>
<tr>
<td>Q3A(R2)</td>
<td>Impurities in New Drug Substances</td>
<td>Oct. 2006</td>
</tr>
<tr>
<td>Q3B(R2)</td>
<td>Impurities in New Drug Products</td>
<td>June 2006</td>
</tr>
<tr>
<td>Q3D</td>
<td>Guideline for Elemental Impurities</td>
<td>Dec. 2014</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Residue on Ignition/Sulphated Ash General Chapter</td>
<td>Nov. 2007</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Extractable Volume of Parenteral Preparations General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Particulate Contamination: Sub-Visible Particles General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Disintegration Test General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on University of Dosage Units General Chapter</td>
<td>Nov. 2013</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Dissolution Test General Chapter</td>
<td>Nov. 2010</td>
</tr>
<tr>
<td>Code</td>
<td>Title</td>
<td>Date</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Sterility Chapter General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Tablet Friability General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis General Chapter</td>
<td>Sept. 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Capillary Electrophoresis General Chapter</td>
<td>June 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Analytical Sieving General Chapter</td>
<td>June 2010</td>
</tr>
<tr>
<td>Q4B</td>
<td>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Bulk Density and Tapped Density of Powders General Chapter</td>
<td>June 2012</td>
</tr>
<tr>
<td>Q5A(R1)</td>
<td>Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin</td>
<td>Sept. 1999</td>
</tr>
<tr>
<td>Q5B</td>
<td>Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products</td>
<td>Nov. 1995</td>
</tr>
<tr>
<td>Q5C</td>
<td>Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products</td>
<td>Nov. 1995</td>
</tr>
<tr>
<td>Q5D</td>
<td>Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/ Biological Products</td>
<td>Jul. 1997</td>
</tr>
<tr>
<td>Q5E</td>
<td>Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process</td>
<td>Nov. 2004</td>
</tr>
<tr>
<td>Q6B</td>
<td>Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products</td>
<td>Mar. 1999</td>
</tr>
<tr>
<td>Q7</td>
<td>Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients</td>
<td>Nov. 2000</td>
</tr>
<tr>
<td>Q8(R1)</td>
<td>Pharmaceutical Development</td>
<td>Nov. 2008</td>
</tr>
<tr>
<td>Q9</td>
<td>Quality Risk Management</td>
<td>Nov. 2005</td>
</tr>
<tr>
<td>Q10</td>
<td>Pharmaceutical Quality System</td>
<td>June 2008</td>
</tr>
<tr>
<td>Q11</td>
<td>Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)</td>
<td>May 2012</td>
</tr>
</tbody>
</table>

**Guidelines released for consultation (Step 2b)**

July 2013
## ICH Guidelines Index

### BATCH S: Safety

#### Finalised Guidelines (Step 4)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1A Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals</td>
<td>Nov. 1995</td>
</tr>
<tr>
<td>S1B Testing for Carcinogenicity of Pharmaceuticals</td>
<td>July 1997</td>
</tr>
<tr>
<td>S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals</td>
<td>Mar. 2008</td>
</tr>
<tr>
<td>S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for</td>
<td>Nov. 2011</td>
</tr>
<tr>
<td>Pharmaceuticals Intended for Human Use</td>
<td></td>
</tr>
<tr>
<td>S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic</td>
<td>Oct. 1994</td>
</tr>
<tr>
<td>Exposure in Toxicity Studies</td>
<td></td>
</tr>
<tr>
<td>Studies</td>
<td></td>
</tr>
<tr>
<td>S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non</td>
<td>Sept. 1998</td>
</tr>
<tr>
<td>Rodent Toxicity Testing)</td>
<td></td>
</tr>
<tr>
<td>S5(R2) Detection of Toxicity to Reproduction for Medicinal Products and</td>
<td>June 1993</td>
</tr>
<tr>
<td>Toxicity to Male Fertility (the Addendum dated November 1995 has been</td>
<td></td>
</tr>
<tr>
<td>incorporated into the core guideline in November 2005)</td>
<td></td>
</tr>
<tr>
<td>S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived</td>
<td>June 2011</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>S7A Safety Pharmacology Studies for Human Pharmaceuticals</td>
<td>Nov. 2000</td>
</tr>
<tr>
<td>S7B The Non-clinical Evaluation of the Potential for Delayed Ventricular</td>
<td>May 2005</td>
</tr>
<tr>
<td>Repolarization (QT Interval Prolongation) by Human Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>S8 Immunotoxicity Studies for Human Pharmaceuticals</td>
<td>Sept. 2005</td>
</tr>
<tr>
<td>S10 Photosafety Evaluation</td>
<td>Nov. 2013</td>
</tr>
</tbody>
</table>

#### Guidelines released for consultation (Step 2b)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>S7B The Non-clinical Evaluation of the Potential for Delayed Ventricular</td>
<td>May 2005</td>
</tr>
<tr>
<td>Repolarization (QT Interval Prolongation) by Human Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>S8 Immunotoxicity Studies for Human Pharmaceuticals</td>
<td>Sept. 2005</td>
</tr>
<tr>
<td>S10 Photosafety Evaluation</td>
<td>Nov. 2013</td>
</tr>
<tr>
<td>Batch E: Efficacy</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---</td>
</tr>
<tr>
<td><strong>Finalised Guidelines</strong> (Step 4)</td>
<td></td>
</tr>
<tr>
<td>E1</td>
<td>The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions</td>
</tr>
<tr>
<td>E2D</td>
<td>Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting</td>
</tr>
<tr>
<td>E2E</td>
<td>Pharmacovigilance Planning</td>
</tr>
<tr>
<td>E2F</td>
<td>Development Safety Update Report</td>
</tr>
<tr>
<td>E3</td>
<td>Structure and Content of Clinical Study Reports</td>
</tr>
<tr>
<td>E3 Q&amp;As (R1)</td>
<td>Structure and Content of Clinical Study Reports – Questions &amp; Answers</td>
</tr>
<tr>
<td>E4</td>
<td>Dose-Response Information to Support Drug Registration</td>
</tr>
<tr>
<td>E5(R1)</td>
<td>Ethnic Factors in the Acceptability of Foreign Clinical Data</td>
</tr>
<tr>
<td>E6(R1)</td>
<td>Good Clinical Practice: Consolidated Guideline</td>
</tr>
<tr>
<td>E7</td>
<td>Studies in Support of Special Populations: Geriatrics</td>
</tr>
<tr>
<td>E7 Q&amp;As</td>
<td>Studies in Support of Special Populations: Geriatrics – Questions &amp; Answers</td>
</tr>
<tr>
<td>E8</td>
<td>General Considerations for Clinical Trials</td>
</tr>
<tr>
<td>E9</td>
<td>Statistical Principles for Clinical Trials</td>
</tr>
<tr>
<td>E10</td>
<td>Choice of Control Group and Related Issues in Clinical Trials</td>
</tr>
<tr>
<td>E11</td>
<td>Clinical Investigation of Medicinal Products in the Pediatric Population</td>
</tr>
<tr>
<td>E14</td>
<td>The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs</td>
</tr>
<tr>
<td>E14 Q&amp;As (R2)</td>
<td>The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs – Questions and Answers</td>
</tr>
<tr>
<td>E15</td>
<td>Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories</td>
</tr>
<tr>
<td>E16</td>
<td>Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions</td>
</tr>
</tbody>
</table>

**Documents released for consultation** (Step 2b)

**Consensus Draft Principle**

### ICH Guidelines Index

#### BATCH M: Multidisciplinary

<table>
<thead>
<tr>
<th>Module</th>
<th>Description</th>
<th>Finalised</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>M3(R2)</td>
<td>Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals</td>
<td>June 2009</td>
<td></td>
</tr>
<tr>
<td>M3(R2) Q&amp;As (R2)</td>
<td>Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions &amp; Answers</td>
<td>Mar. 2012</td>
<td></td>
</tr>
<tr>
<td>M7</td>
<td>Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk</td>
<td>June 2014</td>
<td></td>
</tr>
</tbody>
</table>

#### Guidelines released for consultation (Step 2b)

* **Notice for Clarification:**
  Within the ICH regions, local versions are published. The wording of the core CTD (Modules 2, 3, 4 and 5) in the local versions might be slightly different from one region to another due to specific editing that takes into consideration regional regulations. It does not affect the common understanding by the six ICH parties of the CTD published on the ICH website (http://www.ich.org).

* **Questions & Answers:**
  In order to facilitate the implementation of the CTD, the ICH Experts have developed a series of Q&As which are continuously updated and can be downloaded from the ICH website directly from the following url: http://www.ich.org/products/ctd.html